JMP Securities analyst Reni Benjamin reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $152.00. The company’s shares closed last Friday at $69.59.
According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.0% and a 36.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.
Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $101.27.
The company has a one-year high of $117.86 and a one-year low of $53.26. Currently, Blueprint Medicines has an average volume of 694.6K.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Read More on BPMC:
- IN8bio (INAB) Gets a Buy Rating from Mizuho Securities
- Mizuho Securities Sticks to Their Buy Rating for Neoleukin Therapeutics (NLTX)
- Adaptimmune Therapeutics (ADAP) Receives a Hold from Mizuho Securities
- Stifel Nicolaus Thinks Hasbro’s Stock is Going to Recover
- Stifel Nicolaus Maintains Their Buy Rating on Camden Property (CPT)